Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01390753
Other study ID # INFANT-001
Secondary ID Donor milk study
Status Completed
Phase N/A
First received July 7, 2011
Last updated February 13, 2017
Start date April 2012
Est. completion date December 2016

Study information

Verified date February 2017
Source Fundacion Infant
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute respiratory infections are the leading cause of hospitalization in premature infants worldwide. Severity rates are particularly high in developing countries. Numerous viruses can cause severe disease, but the most frequent agent of hospitalization is respiratory syncytial virus (RSV). In a recent study in Argentina, 58% of RSV infected VLBW infants required hospitalization and 19% required mechanical ventilation. One every twenty infected infants died. Unlike industrialized nations, VLBW infants in developing countries often lack access to prophylaxis against RSV with a commercially available monoclonal antibody (palivizumab). No vaccine or preventive intervention is available against any respiratory virus for infants younger than 6 months of age in developing countries and the public sector of most middle-income countries.

The protective role of breastfeeding against respiratory infections in developing countries is well established. But while similar beneficial effects have been described for premature infants, the dropout rate for breastfeeding in families exposed to the uncertainties and stress of the early months of life in the neonatal intensive care unit is very high. The World Health Organization recommends the use of Human Milk Donor Banks to feed infants that cannot be breastfed by their own mothers. These banks are established with the purpose of collecting, screening, processing (including pasteurizing), testing and distributing donated human milk. The potential benefit of donated milk against acute disease elicited by RSV is unknown. The investigators propose to study the role of supplemental donated human milk in the prevention of hospitalizations caused by RSV in non-breastfeeding premature infants. Since the investigators expect the benefits of breast milk to extend beyond protection against RSV, the effect of human milk against respiratory infections elicited by other viruses will also be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group N/A to 1 Month
Eligibility Inclusion Criteria:

- VLBW preterm neonates (birth weight <1,500 g at birth; gestational age <37 weeks) born alive at any of the two participating maternity hospitals integrating our network in Argentina will be enrolled in the study after signature of informed consent.

Exclusion Criteria:

- VLBW infants older than one month of age (e.g.: transferred from another institution), or formula fed for over ten days, or with congenital heart disease, congenital anomalies of the respiratory tract (i.e.: tracheoesophageal fistula, pulmonary hypoplasia, diaphragmatic hernia), immune suppression, severe malformations affecting breathing (i.e. anencephaly) as well as infants who die prior to completion of the first questionnaire, or living more than 40 km away from the Hospital will be excluded from participation. Infants born from human immunodeficiency virus (HIV) positive mothers will also be excluded

Study Design


Intervention

Dietary Supplement:
Human donor milk


Locations

Country Name City State
Argentina Fundacion INFANT Buenos Aires

Sponsors (1)

Lead Sponsor Collaborator
Fundacion Infant

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of respiratory episodes in premature infants During the first year of life
See also
  Status Clinical Trial Phase
Completed NCT00369759 - An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants N/A
Completed NCT01907659 - Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections N/A
Completed NCT00388921 - High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM N/A
Completed NCT02211729 - A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children Phase 3
Recruiting NCT03093220 - Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis N/A
Recruiting NCT01167686 - Effects of Gardemont S.A Food Supplement on Upper Respiratory Illness Phase 2
Completed NCT00514670 - A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program N/A
Completed NCT02927743 - Effect of Evidence-based Reminders on Use of Antibiotics N/A
Completed NCT02438293 - 'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
Completed NCT04362059 - A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19 N/A
Completed NCT00533182 - Influenza in People With Normal and Weakened Immune Systems
Completed NCT01909128 - Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms Phase 3
Completed NCT00144040 - Improving Antibiotic Use in Acute Care Treatment N/A
Recruiting NCT05474430 - Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
Completed NCT01443728 - Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT02491164 - Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe Early Phase 1